Skip to main content
    P

    Pharvaris BV (PHVS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $29.64
    -0.38 (-1.27%)

    Market Cap: $2.11B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    43%(10/23)
    Avg Surprise
    -10.77%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.72
    Range$-0.80 - $-0.65
    11 analysts
    EPS Revisions
    1
    0
    7d
    3
    8
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.66-8.5%
    60d ago$-0.67-6.9%
    30d ago$-0.72-0.1%
    7d ago$-0.720.0%
    Current$-0.72
    Revenue Consensus
    $0
    Range$0 - $0
    9 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.68
    Range$-0.93 - $-0.31
    13 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    10 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.68---
    Sep 26EST
    		-$-0.72---
    Jun 26
    Reported Aug 12
    		$-0.81$-0.74-9.46%Miss+2.4%
    Mar 26
    Reported Apr 2
    		$-0.71$-0.62-14.52%Miss+16.5%
    Dec 25
    Reported Dec 31
    		$-0.71$-0.62-15.41%Miss-10.9%
    Sep 25
    Reported Nov 12
    		$-0.60$-0.67+10.45%Beat+22.1%
    Jun 25
    Reported Aug 12
    		$-0.83$-0.77-7.79%Miss-50.9%
    Mar 25
    Reported May 13
    		$-0.85$-0.83-2.41%Miss-63.5%
    Dec 24
    Reported Mar 31
    		$-0.64$-0.73+11.91%Beat+22.0%
    Sep 24
    Reported Nov 13
    		$-0.77$-0.60-28.33%Miss-32.8%
    Jun 24
    Reported Aug 14
    		$-0.55$-0.58+5.17%Beat+12.7%
    Mar 24
    Reported Apr 3
    		$-0.52$-0.57+8.77%Beat+22.4%
    Dec 23
    Reported Mar 6
    		$-0.82$-0.58-41.38%Miss+34.4%
    Sep 23
    Reported Nov 2
    		$-0.58$-0.59+1.69%Beat-132.0%
    Jun 23
    Reported Aug 7
    		$-0.63$-0.58-8.62%Miss-65.8%
    Mar 23
    Reported Apr 5
    		$-0.67$-0.76+11.84%Beat-39.6%
    Dec 22
    Reported Dec 31
    		$-1.25$-0.70-78.57%Miss-1288.9%
    Sep 22
    Reported Dec 8
    		$-0.25N/A+60.32%Beat+35.9%
    Jun 22
    Reported Jul 1
    		$-0.38$-0.56+32.14%Beat+59.6%
    Mar 22
    Reported May 11
    		$-0.48$-0.46-4.35%Miss+27.3%
    Dec 21
    Reported Mar 29
    		$-0.09N/A+87.32%Beat+96.6%
    Sep 21
    Reported Nov 10
    		$-0.39$-0.47+17.02%Beat+51.2%
    Jun 21
    Reported Jul 30
    		$-0.94$-0.46-104.35%Miss-
    Mar 21
    Reported Apr 30
    		$-0.66$-0.35-88.57%Miss-
    Dec 20
    Reported Feb 9
    		$-2.65$-1.39-90.65%Miss-
    Sep 19
    Reported Dec 31
    		$-0.80$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-9.03EV/EBITDAN/A
    Price/FCF-11.14xFCF Yield-8.98%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-70.50%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio11.94xQuick Ratio11.94x
    Trading Statistics
    Beta-2.46Avg Volume678.08K
    52-Week High$43.2552-Week Low$20.65

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$30.73
    SMA 20$31.97
    SMA 50$34.54
    SMA 200$30.69
    EMA 10$30.79
    EMA 20$31.93
    EMA 50$33.34
    EMA 200$30.73

    MACD

    Line: -1.40Signal: -1.27Hist: -0.14

    ADX

    ADX: 22.2+DI: 13.7-DI: 24.6

    Aroon & PSAR

    Aroon Up4.0
    Aroon Down100.0
    PSAR$31.28

    Bollinger Bands

    Upper Band$35.77
    Lower Band$28.16
    %B Position2381%(Upper)
    Band Width0.19

    RSI (14-Day)

    Oversold
    28.5

    Momentum Oscillators

    Stoch %K6.4
    Stoch %D7.9
    Williams %R-87.3
    ROC (10d)-4.4%
    Momentum-1.37
    CCI (20d)-99.0
    MFI (14d)21.1

    Volatility Measures

    ATR (14d)$1.46(4.9%)
    StdDev (20d)1.90
    Hist Vol30.8%(Moderate)

    Volume Flow

    VWAP$29.91
    OBV10.1M
    AD Line-9.5M
    CMF (20d)-0.295

    Volume Metrics

    Avg Vol (20d)647.6K
    Vol Ratio1.3x
    VWMA (20d)$31.97

    Pivot Points

    R3$31.15
    R2$30.83
    R1$30.43
    Pivot Point$30.11
    S1$29.71
    S2$29.39
    S3$28.99

    Advanced Oscillators

    TSI-34.41
    Ultimate Osc33.9
    KST-145.34

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$0$0$0$0$0$0
    Cost of Revenue$182,267$106,447N/AN/AN/A$97,024N/AN/A$69,024$71,004N/A$69,908
    Gross Profit$-182,267$-106,447N/AN/AN/A$-97,024N/AN/A$-69,024$-71,004N/A$-69,908
    Operating Expenses$50.79M$44.89M$47.60M$39.66M$40.37M$-42,186,311$45.09M$37.90M$34.38M$28.31M$27.18M$26.20M
    R&D$35.00M$30.66M$34.14M$29.81M$29.61M$30.91M$31.20M$25.78M$23.07M$18.51M$18.61M$18.54M
    SG&A$15.79M$13.46M$13.46M$9.85M$10.77M$11.27M$13.89M$12.12M$11.31M$9.80M$8.57M$7.67M
    Operating Income$-50,788,287$-45,000,039$-47,599,025$-39,664,499$-40,373,097$42.19M$-45,092,034$-37,902,273$-34,382,001$-28,311,859$-27,180,962$-26,201,266
    Interest Income$1.98M$0$0$2.15M$1.00M$1.20M$0$1.98M$2.11M$63,921$0$66,576
    Interest Expense$73,800$87,823$0$0$4.90M$88.22M$0$9,135$2.60M$0$4.82M$0
    Income Before Tax$-47,240,529$-39,567,716$-45,076,932$-37,318,504$-45,277,904$-46,038,156$-33,521,747$-41,480,667$-29,660,450$-27,733,639$-31,999,953$-23,452,323
    Income Tax Expense$602,200$277,597$0$-181,469$202,782$302,667$0$230,091$70,623$285,117$0$146,273
    Net Income$-47,842,729$-39,845,314$-46,740,853$-37,137,035$-45,480,686$-46,340,823$-34,760,940$-41,710,758$-29,731,073$-28,018,756$-32,747,650$-23,598,596
    EBITDA$-50,608,988$-39,373,446$-47,494,157$-37,213,352$-45,174,872$-42,081,010N/A$-41,427,960$-29,591,773$-27,667,284N/A$-26,133,333
    EBIT$-50,788,287$-39,479,893$-47,599,025$-37,318,504$-45,277,904$-42,186,311N/A$-41,471,532$-29,660,450$-27,733,639N/A$-26,201,266
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about PHVS

    News

    Form 4 Pharvaris N.V.: Peng Lu (President) For: 11 October By Investing.com

    This article reports on a Form 4 filing for Pharvaris N.V., indicating that Peng Lu, the President, made a transaction on October 11. The piece serves as a brief financial markets update from Investing.com...

    Investing.com Nigeria•10/14/26•Neutral

    Form 4 Pharvaris N.V.: Peng Lu (President) For: 11 October By Investing.com

    This article reports on a Form 4 filing for Pharvaris N.V., indicating that Peng Lu, the President, had a transaction on October 11. The article is a brief financial news item from Investing.com...

    Investing.com India•10/14/26•Neutral

    Form 4 Pharvaris N.V.: Peng Lu (President) For: 11 October By Investing.com

    This article reports on a Form 4 filing for Pharvaris N.V. (PHVS) indicating activity by its President, Peng Lu...

    Investing.com UK•10/14/26•Neutral

    Understanding the Setup: (PHVS) and Scalable Risk

    This article analyzes Pharvaris N.v. (PHVS) using AI models to provide insights into its near-term, mid-term, and long-term outlook. It identifies positive near-term sentiment but a potential for mid-term weakness within...

    Stock Traders Daily•10/13/26•Neutral

    Pharvaris N.V. (PHVS) stock price, news, quote and history

    This article provides a detailed financial overview of Pharvaris N.V. (PHVS), including its current stock price, historical performance, key financial metrics...

    Yahoo Finance Singapore•10/10/26•Neutral

    PHVS Valuation and Fair Value

    P/E
    -9.0x
    P/FCF
    -11.1x
    P/B
    5.9x
    See GNG's fair value

    PHVS Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -70.5%
    FCF yield
    -9.0%

    PHVS Competitors

    CompanyTicker
    Dynavax Technologies CorporationDVAX
    Avadel Pharmaceuticals PLCAVDL
    Progyny IncPGNY
    Novavax IncNVAX
    Disc Medicine Inc.IRON
    BioCryst Pharmaceuticals IncBCRX
    Aurinia Pharmaceuticals IncAUPH
    Viridian Therapeutics IncVRDN

    Sector: Healthcare

    PHVS Analyst Ratings

    Consensus
    Buy
    Analysts
    14
    Strong Buy
    3
    Buy
    10
    Hold
    1
    Sell
    0
    Strong Sell
    0

    PHVS Bull Case vs Bear Case

    Bull case

    • 92.9% of PHVS's analyst ratings are Buy or Strong Buy.

    Bear case

    • PHVS beat EPS estimates in 25.0% of its last 8 reported quarters.

    PHVS Earnings: Beat Rate and Next Report

    Beat rate
    2 of 8 quarters (25.0%)
    Average surprise
    -6.9%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.72
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    3 up, 8 down

    Frequently Asked Questions About PHVS

    Does PHVS pay dividends?

    Pharvaris BV (PHVS) does not currently pay a regular dividend.

    What is PHVS's market cap?

    Pharvaris BV (PHVS) has a market capitalization of $2.11B with a current stock price of $29.64.

    Related stocks

    Sector: Healthcare

    All stocks starting with P

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In